Compare BRT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRT | CDXS |
|---|---|---|
| Founded | 1972 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Major Chemicals |
| Sector | Real Estate | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.9M | 256.3M |
| IPO Year | 1994 | 2008 |
| Metric | BRT | CDXS |
|---|---|---|
| Price | $14.93 | $2.42 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $19.75 | N/A |
| AVG Volume (30 Days) | 21.5K | ★ 780.9K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.03% | N/A |
| EPS Growth | N/A | ★ 43.82 |
| EPS | N/A | ★ N/A |
| Revenue | $97,028,000.00 | ★ $138,590,000.00 |
| Revenue This Year | $3.82 | $7.73 |
| Revenue Next Year | $5.35 | $14.24 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 1.46 | ★ 32.30 |
| 52 Week Low | $13.18 | $0.96 |
| 52 Week High | $16.69 | $3.87 |
| Indicator | BRT | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 62.89 | 43.87 |
| Support Level | $14.23 | $2.39 |
| Resistance Level | $14.93 | $2.88 |
| Average True Range (ATR) | 0.33 | 0.15 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 76.34 | 12.17 |
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
Codexis Inc is a biotechnology company engaged in providing enzyme-based technology solutions to improve pharmaceutical manufacturing processes. The company operates through two key business areas: the ECO Synthesis manufacturing platform and small molecule pharma biocatalysis. The ECO Synthesis platform focuses on developing enzymatic processes for the large-scale manufacture of RNA interference therapeutics, while the biocatalysis business utilizes engineered enzymes to enhance efficiency, yield, and sustainability in small molecule drug manufacturing. Geographically, it derives maximum revenue from the Americas.